Supplementary Figure 1 from Identification of Biomarkers Including ¹⁸FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

Supplementary Figure 1: Graphical display of changes in primary tumor SUVmax between baseline and interim 18F-FDG PET exams.</p

Supplementary Figure 1 from Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors

PDF file - 68K, Individual median of free to VEGF-bound aflibercept Ctrough ratio observed from cycle.</p

Reasons for disagreement between EORTC criteria and PERCIST (reader 1).

Reasons for disagreement between EORTC criteria and PERCIST (reader 1).</p

A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study

<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>. </b><a href="https://link.springer.com/article/10.1007/s40487-016-0027-x">https://link.springer.com/article/10.1007/s40487-016-0027-x</a></p><p></p> <p><br></p> <p><b>Provide enhanced content for this article</b></p> <p><br></p> <p>If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <a href="http://www.medengine.com/Redeem/”mailto:[email protected]”"><b>[email protected]</b></a>.</p> <p><br></p> <p>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.</p> <p><br></p> <p>Other enhanced features include, but are not limited to:</p> <p><br></p> <p>• Slide decks</p> <p>• Videos and animations</p> <p>• Audio abstracts</p> <p>• Audio slides</p

Follow up PET with a different location of the highest SULpeak target lesion (PERCIST).

<p>Blue spot corresponding to the lesion having the highest SULpeak (target lesion). This follow up scan having a different target lesion, now located on the right lobe of the liver.</p

Summary of EORCT and PERCIST evaluation methods.

<p>Summary of EORCT and PERCIST evaluation methods.</p

Agreement and corresponding kappa coefficient between readers for EORCT and PERCIST.

<p>Agreement and corresponding kappa coefficient between readers for EORCT and PERCIST.</p

Agreement between EORTC criteria and PERCIST (reader 2).

<p>Agreement between EORTC criteria and PERCIST (reader 2).</p

Cox regression univariate and multivariate analysis for prediction of death (reader 1).

<p>Cox regression univariate and multivariate analysis for prediction of death (reader 1).</p

Agreement between EORTC criteria and PERCIST (reader 1).

<p>Agreement between EORTC criteria and PERCIST (reader 1).</p